Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
Aliskiren
NOVARTIS (SINGAPORE) PTE LTD
C09XA02
300mg
TABLET, FILM COATED
ORAL
Prescription Only
Novartis Pharma Stein AG
2008-07-09
RASILEZ Renin inhibitor DESCRIPTION AND COMPOSITION PHARMACEUTICAL FORM Film-coated tablet. ACTIVE SUBSTANCE The active substance is 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4- hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide hemifumarate (INN – Aliskiren hemifumarate). One film-coated tablet contains 150 mg or 300 mg aliskiren hemifumarate. . Certain dosage strengths may not be available in all countries. ACTIVE MOIETY Aliskiren EXCIPIENTS Standard film-coated tablet: Crospovidone; magnesium stearate; microcrystalline cellulose; povidone; silica, colloidal anhydrous; hypromellose; macrogol; talc; iron oxide, black (E 172); iron oxide, red (E 172); titanium dioxide (E 171). Pharmaceutical formulations may vary between countries. INDICATIONS Treatment of essential hypertension. DOSAGE AND ADMINISTRATION DOSAGE GENERAL TARGET POPULATION The recommended starting dose of Rasilez is 150 mg once daily. In patients whose blood pressure is not adequately controlled, the dose may be increased to 300 mg once daily. The antihypertensive effect is substantially present within 2 weeks (85 to 90%) after initiating therapy with 150 mg once daily. Rasilez may be used alone or in combination with other antihypertensive agents (diuretics, and calcium channel blockers) (See section PHARMACODYNAMICS). It must not be used in combination with Angiotensin Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARB) in patients with type 2 diabetes mellitus. (see sections CONTRAINDICATIONS and INTERACTIONS). METHOD OF ADMINISTRATION Patients should establish a routine pattern for taking Ra Read the complete document